Terpenes are emerging as a new complementary therapy for several chronic diseases, but their effects on inflammatory cytokines are not...
Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare...
Cannabidiol (CBD) is a major phytocannabinoid present in *Cannabis sativa* (Linneo, 1753). This naturally occurring secondary metabolite does not induce...
Cannabidiol (CBD), a cannabinoid that does not create psychoactive activities, has been identified as having a multitude of therapeutic benefits....
Cardiovascular disease (CVD) causes millions of deaths worldwide each year. Despite the great progress in therapies available for patients with...
A large number of cannabinoids have been discovered that could play a role in mitigating cardiac affections. However, none of...
Odontogenic pain can be debilitating, and nonopioid analgesic options are limited. This randomized placebo-controlled clinical trial aimed to assess the...
Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the...
Despite current therapeutic strategies for immunomodulation and relief of symptoms in multiple sclerosis (MS), remyelination falls short due to dynamic...
Due to the myriad of laws concerning cannabis, there is little empirical research regarding the veterinary use of cannabidiol (CBD)....
© 2025 · Veterinary Cannabis Society